I just keep thinking about the highly significant reduction in brain matter loss for A 2-73 vs placebo. Brain matter loss leads to all that is Alzheimer's. This treatment will be submitted for approval and it will be approved in multiple locations in time. Ultimately, Blarcamesine will become a treatment of choice for multiple CNS issues...and Anavex will become a mega Pharma unless bought out. In the meantime still have some buy orders sitting in case the market chooses to fill them...
Market Data 
Markets 
AI
